These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Protective activity and immunogenicity of two recombinant anthrax vaccines for veterinary use. Fasanella A; Tonello F; Garofolo G; Muraro L; Carattoli A; Adone R; Montecucco C Vaccine; 2008 Oct; 26(45):5684-8. PubMed ID: 18775462 [TBL] [Abstract][Full Text] [Related]
26. Anthrax protective antigen administered by DNA vaccination to distinct subcellular locations potentiates humoral and cellular immune responses. Midha S; Bhatnagar R Eur J Immunol; 2009 Jan; 39(1):159-77. PubMed ID: 19130551 [TBL] [Abstract][Full Text] [Related]
27. A Comparison of the Adaptive Immune Response between Recovered Anthrax Patients and Individuals Receiving Three Different Anthrax Vaccines. Laws TR; Kuchuloria T; Chitadze N; Little SF; Webster WM; Debes AK; Saginadze S; Tsertsvadze N; Chubinidze M; Rivard RG; Tsanava S; Dyson EH; Simpson AJ; Hepburn MJ; Trapaidze N PLoS One; 2016; 11(3):e0148713. PubMed ID: 27007118 [TBL] [Abstract][Full Text] [Related]
28. Randomized, double-blind, active-controlled study evaluating the safety and immunogenicity of three vaccination schedules and two dose levels of AV7909 vaccine for anthrax post-exposure prophylaxis in healthy adults. Hopkins RJ; Kalsi G; Montalvo-Lugo VM; Sharma M; Wu Y; Muse DD; Sheldon EA; Hampel FC; Lemiale L Vaccine; 2016 Apr; 34(18):2096-105. PubMed ID: 26979136 [TBL] [Abstract][Full Text] [Related]
29. Validation of an anti-PA-ELISA for the potency testing of anthrax vaccine in mice. Pombo M; Berthold I; Gingrich E; Jaramillo M; Leef M; Sirota L; Hsu H; Arciniega J Biologicals; 2004 Sep; 32(3):157-63. PubMed ID: 15536047 [TBL] [Abstract][Full Text] [Related]
31. A case of naturally acquired inhalation anthrax: clinical care and analyses of anti-protective antigen immunoglobulin G and lethal factor. Walsh JJ; Pesik N; Quinn CP; Urdaneta V; Dykewicz CA; Boyer AE; Guarner J; Wilkins P; Norville KJ; Barr JR; Zaki SR; Patel JB; Reagan SP; Pirkle JL; Treadwell TA; Messonnier NR; Rotz LD; Meyer RF; Stephens DS Clin Infect Dis; 2007 Apr; 44(7):968-71. PubMed ID: 17342650 [TBL] [Abstract][Full Text] [Related]
32. [Immunogenicity of the recombinant Bacillus strains with cloned gene of biosynthesis of protective antigen against Bacillus anthracis]. Mikshis NI; Kudriavtseva OM; Bolothikova MF; Shulepov DV; Novikova LV; Popov IuA; Shchukovskaia TN; Drozdov IG; Kutyrev VV Mol Gen Mikrobiol Virusol; 2007; (3):15-21. PubMed ID: 17886469 [TBL] [Abstract][Full Text] [Related]
33. A two-stage, multilevel quality control system for serological assays in anthrax vaccine clinical trials. Soroka SD; Schiffer JM; Semenova VA; Li H; Foster L; Quinn CP Biologicals; 2010 Nov; 38(6):675-83. PubMed ID: 20875951 [TBL] [Abstract][Full Text] [Related]
34. Anthrax vaccines. Splino M; Patocka J; Prymula R; Chlibek R Ann Saudi Med; 2005; 25(2):143-9. PubMed ID: 15977694 [TBL] [Abstract][Full Text] [Related]
35. Gorse GJ, et al. "Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial" [Vaccine 24 (2006) 5950-5959]. Zink TK Vaccine; 2007 Apr; 25(15):2766-7. PubMed ID: 17224206 [TBL] [Abstract][Full Text] [Related]
36. Anthrax vaccine: immunogenicity and safety of a dose-reduction, route-change comparison study in humans. Pittman PR; Kim-Ahn G; Pifat DY; Coonan K; Gibbs P; Little S; Pace-Templeton JG; Myers R; Parker GW; Friedlander AM Vaccine; 2002 Jan; 20(9-10):1412-20. PubMed ID: 11818160 [TBL] [Abstract][Full Text] [Related]
37. [Serological study carried out in Cambodia during a tetanus vaccination in adults]. Schlumberger M; Yvonnet B; Que HV; Chhem DB; Saliou P; Le Tu TC; Glaziou P Bull Soc Pathol Exot; 2008 Feb; 101(1):36-42. PubMed ID: 18432006 [TBL] [Abstract][Full Text] [Related]
38. Anthrax, toxins and vaccines: a 125-year journey targeting Bacillus anthracis. Tournier JN; Ulrich RG; Quesnel-Hellmann A; Mohamadzadeh M; Stiles BG Expert Rev Anti Infect Ther; 2009 Mar; 7(2):219-36. PubMed ID: 19254170 [TBL] [Abstract][Full Text] [Related]
39. Immunogenicity and safety of four different dosing regimens of anthrax vaccine adsorbed for post-exposure prophylaxis for anthrax in adults. Bernstein DI; Jackson L; Patel SM; El Sahly HM; Spearman P; Rouphael N; Rudge TL; Hill H; Goll JB Vaccine; 2014 Oct; 32(47):6284-93. PubMed ID: 25239484 [TBL] [Abstract][Full Text] [Related]
40. A study of the physiology of Bacillus anthracis Sterne during manufacture of the UK acellular anthrax vaccine. Charlton S; Herbert M; McGlashan J; King A; Jones P; West K; Roberts A; Silman N; Marks T; Hudson M; Hallis B J Appl Microbiol; 2007 Nov; 103(5):1453-60. PubMed ID: 17953556 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]